Clinical utility and patient adherence with ebastine for allergic rhinitis
Giorgio CiprandiDepartment of Internal Medicine, San Martino Hospital, Genoa, ItalyAbstract: Allergic rhinitis (AR) is a high prevalence disease, affecting 10%–20% of the general population. AR is sustained by an IgE-mediated reaction, and by a complex inflammatory network of cells, me...
Main Author: | Giorgio Ciprandi |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2010-10-01
|
Series: | Patient Preference and Adherence |
Online Access: | http://www.dovepress.com/clinical-utility-and-patient-adherence-with-ebastine-for-allergic-rhin-a5507 |
Similar Items
-
Ebastine in the treatment of patients with allergic rhinitis
by: A. Yu. Ovchinnikov, et al.
Published: (2019-08-01) -
Symptom Severity and Allergen-specific IgE in Allergic Rhinitis
by: Giorgio Ciprandi
Published: (2017-02-01) -
Probiotics in Allergic Rhinitis Management: Is There a Positioning for Them?
by: Giorgio Ciprandi, et al.
Published: (2022-09-01) -
Self-Management in Allergic Rhinitis: Strategies, Outcomes and Integration into Clinical Care
by: Ciprandi G
Published: (2023-10-01) -
The impact of allergic rhinitis on bronchial asthma: What therapy?
by: Maria Angela Tosca, et al.
Published: (2024-03-01)